By Adam Andrzejewski for RealClearPolicy
The U.S. desperately tried to find enough Covid-19 rapid-antigen tests. It gave $10.3 million to a South Korean biotech firm to develop a better test. Because of its inaccuracy, Utah has decided to stop using it.
According to an investigation by Judicial Watch, the U.S. Department of Health and Human Services gave the funding to South Korean biotech company GenBody.
It was first used in Utah’s state-run testing facilities in December 2021. In February 2022 Utah stopped its use due to its 60 percent false-negative rate. While rapid tests are typically less accurate than PCR — polymerase chain reaction — tests, the high inaccuracy rate made the tests useless.
RELATED : PPP Federal Covidaid Wrongly Given to Unions $36.7 million
Whenever money is given for research and development, there’s a chance the new product won’t work. Why was an FDA-approved test that had a 40% accuracy rate approved?
It’s also worth questioning why this money went to a South Korean firm. America has the best biotech companies and scientists in the world. It is a mystery why all that money had to go abroad.
American citizens deserve transparency and clarity from their government, despite all of the confusion and misinformation surrounding the Covid-19 pandemic.
Support Conservative Voices!
Register to Receive the LatestGet political news, insights, and commentary directly delivered to your email inbox
Real Clear Wire permission granted permission for this syndicated article.
OpenTheBooks.com presents the #WasteOfTheDay.
Contributors and/or content partners may express their opinions, but they do not reflect those of The Political Insider.